PUBLISHER: Grand View Research | PRODUCT CODE: 2067463
PUBLISHER: Grand View Research | PRODUCT CODE: 2067463
The global viral vector bioanalytical testing services market size was estimated at USD 578.5 million in 2025 and is projected to reach USD 1,155.7 million by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market growth is attributed to an increasing number of gene and cell therapy pipelines, rising regulatory focus on safety and potency validation, growing demand for AAV and lentiviral vectors, increasing clinical trial activity, and the expansion of biologics and advanced therapeutics, which are increasing testing volumes and outsourcing, in turn, boosting the demand for viral vector bioanalytical testing services.
The increasing number of clinical pipelines for cell and gene therapies, the rise in stringency in terms of regulatory requirements for characterization of viral vectors, increased use of AAV and lentivirus vectors in gene and cell therapies respectively, growing use of outsourcing by companies for their clinical and preclinical studies, advances in analytical techniques such as digital PCR and NGS, and complexities associated with the development of more complex and sensitive potencies and safety assays contribute towards increased demand for viral vector bioanalysis testing services. Furthermore, with the expansion of clinical pipelines, the need for more repetitive testing and a high volume of testing during clinical phases has increased revenue contribution from clinical phase testing processes.
In addition, regulatory authorities impose stringent requirements for safety, potency, and purity testing, which would result in increased expenditure for companies developing gene and cell therapies, with a focus on outsourcing testing services through long-term contracts. The aforesaid factors are expected to drive market growth over the forecast period. Additionally, innovations like digital PCR and next-generation sequencing (NGS) help boost sensitivity and efficiency, thus allowing detection of impurities even in very small concentrations while providing better compliance. Thus, the shift from regular assays to valuable testing services is likely to increase the demand for bioanalytical services. Also, outsourcing activities amongst small and medium biotech organizations creates greater reliance on CROs owing to limited capacity within these companies, thus making these companies outsource more frequently.
Nevertheless, the higher prices of bioanalytical testing, along with the lack of uniformity across assays, hinder the use of such technologies by startup companies, and differences in regulatory requirements across regions complicate operations for service providers. Thus, these factors are collectively impacting the market growth of the viral vector bioanalytical testing services industry.
Global Viral Vector Bioanalytical Testing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viral vector bioanalytical testing services market based on test, viral vector, development stage, end-use, and region: